NEWS RELEASE

2021.05.04

Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH

Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH.

 

For detailed information, see the below URL.

https://www.prnewswire.com/news-releases/chemomab-announces-enrollment-of-first-patient-in-phase-2a-study-of-cm-101-in-non-alcoholic-steatohepatitis-nash-301276524.html?tc=eml_cleartime

 

CM-101, a monoclonal antibody designed to bind and block CCL24 activity.  The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement of NASH and fibrosis in the STAM™ mouse model was published in JHEP Reports.

https://www.sciencedirect.com/science/article/pii/S2589555919301582

 

In the future, we believe that further clinical trial results for CM-101 will provide evidence for the STAM™ mouse model as a clinically predictive NASH model.